References
- Louie K G, Ozols R F, Myers C E. Long-term results of a cisplatin-contairang combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J Clin Oncol 1986; 4: 1579–1585
- Young R C, VonHoff D D, Gormley P. Cis-dichlorodiammineplatinum (II) for the treatment of advanced ovarian cancer. Cancer Treat Rep 1979; 63: 1539–1544
- Foster B J, Clagett-Carr K, Marsoni S. Role of hemamethyl-melamine in the treatment of ovarian cancer Where is the needle in the haystack. Cancer Treat Rep 1986; 70: 1003–1014
- Levin L, Hryniuk W M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756–767
- Vogl S E, Pagano M, Davis T E. Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy. Cancer Treat Rep 1982; 66: 1285–1290
- Fabian C J, Rasmussen S, Stephens R. Phase II evaluation of hexamethylmelamine in advanced breast cancer: A Southwest Oncology Group study. Cancer Treat Rep 1979; 63: 1359–1361
- Vogl S E, Seltzer V, Canalog A. Laparotomy with therapeutic intent after 6 months of induction chemotherapy for bulky ovarian cancer. New Approaches in Cancer Therapy, H Cortes Funes, M. Rozencweig. Raven Press, New York 1982; 117–125
- Oken M M, Creech R H, Tormey D C. Toxicity and response criteria of the Eastern Cooperative Oncology Group. J Clin Oncol 1982; 5: 649–655
- Mehta C R, Patel N R. A network algorithm for performing Fisher's exact test in rxc contingency tables. J Am Stat Assoc 1983; 78: 427–434
- Cox D R. Analysis of Binary Data. Chapman and Hall, London 1970
- Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170
- Cox D R. Regression models and life tables. J Royal Stat Soc (Series B) 1972; 34: 187–220
- Mehta C R, Patel N R, Tsiatis A A: Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics 1984; 40: 819–825
- Barker G H, Wiltshaw E: Use of high-dose cir-dichlorodiamine platinum (II) following failure on previous chemotherapy for advanced carcinoma of the ovary. Br J Obstet Med 1981; 88: 1192–1199
- Bruckner H W, Wallaeh R. High-dose cisplatinum for the treatment of refractory ovarian cancer. Gynecol Oncol 1984; 12: 64–67
- Ozols R F, Ostchega Y, Myers C E. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 1985; 3: 1246–1250
- Sutton G P, Stehman F B, Einhorn L H. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 1989; 7: 223–229
- Hainsworth J D, Grosh W W, Burnett L S. Advanced ovarian cancer: Long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med 1988; 108: 165–170
- Piver M S, Lele S B, Marchetti D L. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 1988; 6: 983–989
- Omura G A, Bundy B N, Berek J S. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Study Group study. J Clin Oncol 1989; 7: 457–465
- Fuks Z, Rizel S, Biran S. Chemotherapeutic and surgical induction of pathologial complete remission and whole abdominal irradiation for consolidation does not enhance the cure of stage HI ovarian carcinoma. J Clin Oncol 1988; 6: 509–516
- Van Houwelingen J C, Ten BokkelHuinink W W, Van derBurg M EL. Predictability of the survival of patients with advanced cancer. J Clin Oncol 1989; 7: 769–773
- Vogl S E, Greenwald E, Kaplan B H. Ovarian cancer. Effective treatment after alkylating-agent failure. J Am Med Assoc 1908–1911; 241, 1979